Literature DB >> 30359082

5-HT3 receptor signaling in serotonin transporter-knockout rats: a female sex-specific animal model of visceral hypersensitivity.

Nadine El-Ayache1, James J Galligan1,2.   

Abstract

The irritable bowel syndrome (IBS) is a functional gastrointestinal motor and visceral sensation disorder that is more common in women than men. Female serotonin transporter (SERT)-gene knockout (KO) rats exhibit hypersensitivity to colorectal balloon distention (CRD) that mimics colonic hypersensitivity occurring in female IBS patients. Alosetron (5-HT3 receptor antagonist) is used to treat diarrhea-predominant IBS in female patients. Other 5-HT3 receptor antagonists are ineffective at treating IBS symptoms. The visceromotor response (VMR) to CRD in SERT-KO and wild-type (WT) rats was measured following subcutaneous (sc), intracerobroventricular (icv), or intrathecal (it) treatment with 5-HT3 receptor antagonists and an agonist. Alosetron (sc) and granisetron (antagonists) caused a paradoxical increase in the VMR to CRD in SERT-KO female rats. Alosetron (sc) increased the VMR to CRD in WT male rats. Alosetron (it) increased the VMR to CRD in SERT-KO female rats only, and the 5-HT3 receptor agonist SR-52772 increased the VMR to CRD in SERT-KO male rats. Depletion of spinal 5-HT using 5,7-dihydroxytryptamine prevented the increase in VMR to CRD in SERT-KO female and male rats treated it with alosetron and SR-52772, respectively. Alosetron (icv) did not affect the VMR to CRD in WT or KO female rats, but it increased the VMR in male SERT-KO but not WT male rats. These data suggest that 5-HT3 receptor signaling at the dorsal spinal cord mediates visceral hypersensitivity in female SERT-KO rats. Such differences could facilitate development of sex-specific drug treatments for visceral pain. NEW & NOTEWORTHY We studied a model of female sex-specific visceral hypersensitivity using rats that had a loss of function of the serotonin transporter (SERT) caused by gene truncation. Female SERT-KO rats exhibited visceral hypersensitivity in response to colorectal balloon distention. We found that increased 5-HT signaling at dorsal spine 5-HT3 receptors was responsible for visceral hypersensitivity in female but not male SERT-KO rats.

Entities:  

Keywords:  5-hydroxytryptamine receptors; irritable bowel syndrome; serotonin transporter; sex differences; visceral pain

Mesh:

Substances:

Year:  2018        PMID: 30359082      PMCID: PMC6383387          DOI: 10.1152/ajpgi.00131.2018

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  57 in total

Review 1.  Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.

Authors:  H Wolf
Journal:  Scand J Rheumatol Suppl       Date:  2000

Review 2.  Biomechanics of the gastrointestinal tract.

Authors:  H Gregersen; G Kassab
Journal:  Neurogastroenterol Motil       Date:  1996-12       Impact factor: 3.598

3.  Association of genetic polymorphisms in HTR3A and HTR3E with diarrhea predominant irritable bowel syndrome.

Authors:  Qiao-Yan Gu; Jun Zhang; Yi-Chao Feng; Guang-Rong Dai; Wei-Ping Du
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat.

Authors:  N M Clayton; R Sargent; A Butler; J Gale; M P Maxwell; A A Hunt; V J Barrett; D Cambridge; C Bountra; P P Humphrey
Journal:  Neurogastroenterol Motil       Date:  1999-06       Impact factor: 3.598

5.  Gender differences in regional brain response to visceral pressure in IBS patients.

Authors:  S Berman; J Munakata; B D Naliboff; L Chang; M Mandelkern; D Silverman; E Kovalik; E A Mayer
Journal:  Eur J Pain       Date:  2000       Impact factor: 3.931

6.  The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.

Authors:  C M Kozlowski; A Green; D Grundy; F M Boissonade; C Bountra
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

7.  Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.

Authors:  A Langlois; X Pascaud; J L Junien; S G Dahl; P J Rivière
Journal:  Eur J Pharmacol       Date:  1996-12-27       Impact factor: 4.432

8.  Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.

Authors:  K M Koch; B W Corrigan; J Manzo; C D James; R J Scott; A G Stead; K E Kersey
Journal:  Aliment Pharmacol Ther       Date:  2004-07-15       Impact factor: 8.171

9.  Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.

Authors:  Steven M Berman; Lin Chang; Brandall Suyenobu; Stuart W Derbyshire; Jean Stains; Leah Fitzgerald; Mark Mandelkern; Lynn Hamm; Brent Vogt; Bruce D Naliboff; Emeran A Mayer
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

Review 10.  The epidemiology of irritable bowel syndrome.

Authors:  Caroline Canavan; Joe West; Timothy Card
Journal:  Clin Epidemiol       Date:  2014-02-04       Impact factor: 4.790

View more
  3 in total

Review 1.  Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission.

Authors:  Adam Shute; Dominique G Bihan; Ian A Lewis; Yasmin Nasser
Journal:  Front Neurosci       Date:  2022-06-23       Impact factor: 5.152

Review 2.  Sex as a biological variable in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  Neurogastroenterol Motil       Date:  2020-01-13       Impact factor: 3.598

3.  SAHA Alleviates Diarrhea-Predominant Irritable Bowel Syndrome Through Regulation of the p-STAT3/SERT/5-HT Signaling Pathway.

Authors:  Jian Shen; Bimeng Zhang; Jianjie Chen; Jiazheng Cheng; Jiali Wang; Xianhui Zheng; Yu Lan; Xiaowen Zhang
Journal:  J Inflamm Res       Date:  2022-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.